查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1795369

稳定同位素标记生物分子的全球市场

Stable Isotope Labeled Biomolecules
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 169 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球稳定同位素标记生物分子市场规模将达到 5.17 亿美元

2024年，全球稳定同位素标记生物分子市场规模估计为3.711亿美元，预计到2030年将达到5.17亿美元，在2024-2030年的分析期内，复合年增长率为5.7%。 D标记生物分子是本报告分析的细分市场之一，预计其复合年增长率为5.4%，到分析期结束时达到3.08亿美元。 15N标记生物分子细分市场在分析期间的复合年增长率估计为6.6%。

美国市场规模估计为 9,760 万美元，中国市场预计复合年增长率为 5.5%

美国稳定同位素标记生物分子市场规模预计在2024年达到9,760万美元。作为世界第二大经济体，中国预计到2030年市场规模将达到8,290万美元，在2024-2030年的分析期间内，复合年增长率为5.5%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个国家的复合年增长率分别为5.0%和4.9%。在欧洲，预计德国的复合年增长率为4.6%。

全球稳定同位素标记生物分子市场－主要趋势与驱动因素摘要

是什么推动了稳定同位素标记生物分子研究的成长？

稳定同位素标记的生物分子，包括13C、15N和2H标记的胺基酸、核苷酸、脂质和代谢物，是蛋白质体学、代谢体学、药物动力学和示踪研究的重要工具。它们可用于质谱分析、同位素稀释定量、MRI成像剂、细胞示踪实验和代谢通量分析。主要终端使用者包括学术实验室、药物研发、生物製造品质控制和石化测试。

诸如精确定量、通路图谱绘製和品质保证等复杂工作流程依赖于根据同位素类型和标记位点定制的高纯度标记标准品。製造商定制用于细胞培养掺入、内标和成像应用的分子。液相层析串联质谱 (LC-MS/MS) 和碎片分析中分析仪器和软体的进步，推动了对稳定同位素标准品的需求。

生产和客製化平台是否提高了可用性？

该公司正在扩大生物合成（利用标记前体的微生物发酵）、化学合成和酶促生物转化工艺，以生产高纯度同位素。新平台支援位点特异性标记和标记组合（例如双13C-15N），从而实现详细的代谢分析。采用快速层析法和高效液相层析的自动化纯化系统可提高通量并降低成本。

优化的交付时间——快速客製化批次以满足製药公司的时间表——由数位订购入口网站和样品交付追踪提供支援。专为药物代谢研究和微生物通量评估量身定制的多同位素试剂套件正在推动CRO和生物製造商的采用。

为什么研究者要跨领域整合这些工具？

定量生物学家和药理学家利用同位素标记标准品进行绝对浓度测量、清除率分析和药物间相互作用研究。系统生物学家使用标记前驱物追踪天然产物的生物合成途径。作物和环境研究人员使用标记代谢物追踪土壤-植物系统中的吸收和转化。在临床营养研究中，稳定同位素液体示踪剂可以非侵入性地追踪吸收和代谢过程。监管机构要求在品管实验室中使用标记内标进行测定验证和批次放行测试。

是什么推动了稳定同位素标记生物分子市场的成长？

稳定同位素标记生物分子市场的成长受到与研究精度、生产可扩展性和跨学科应用相关的多种因素的驱动。发酵和化学标记方法的进步正在降低成本并扩大复杂同位素的可用性。全球对蛋白质体学、代谢体学和药物研发管线的投资不断增加，支持了对高品质参考材料的需求。客製化的短期合成和承包标准试剂套件可满足合约研究组织 (CRO)、生物製药公司和学术机构的时间表。监管机构对药品和食品安全检测中准确定量的期望也在推动其广泛应用。此外，仪器供应商和同位素供应商之间的伙伴关係实现了整合工作流程，将标记参考材料与样品製备、分析和软体相结合，从而加快了获得结果的时间并提高了研究品质。

部分

模式种（D标记生物分子、15N标记生物分子、13C标记生物分子）；最终用户（科研、医疗）

受访公司范例

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris（IsoSciences）
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA（Sigma-Aldrich）
  • NIST
  • Nordion（Canada）, Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP38103

Global Stable Isotope Labeled Biomolecules Market to Reach US$517.0 Million by 2030

The global market for Stable Isotope Labeled Biomolecules estimated at US$371.1 Million in the year 2024, is expected to reach US$517.0 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. D Labeled Biomolecules, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$308.0 Million by the end of the analysis period. Growth in the 15N Labeled Biomolecules segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$97.6 Million While China is Forecast to Grow at 5.5% CAGR

The Stable Isotope Labeled Biomolecules market in the U.S. is estimated at US$97.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$82.9 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Stable Isotope Labeled Biomolecules Market - Key Trends & Drivers Summarized

What’s Driving Growth in Stable Isotope Labeled Biomolecules for Research?

Stable isotope labeled biomolecules-such as ¹³C, ¹5N, ²H labeled amino acids, nucleotides, lipids, and metabolites-are critical tools in proteomics, metabolomics, pharmacokinetics, and tracer studies. Used in mass spectrometry assays, isotope dilution quantification, MRI imaging agents, cell tracing experiments, and metabolic flux analysis. Major end-users include academic labs, pharma R&D, biomanufacturing QC, and petrochemical testing.

Complex workflows-accurate quantification, pathway mapping, quality assurance-depend on access to high-purity labeled standards customized by isotope type and labeling sites. Manufacturers tailor molecules for cell-culture incorporation, internal standardization, and imaging applications. Analytical instrumentation and software advancements in LC-MS/MS and fragment analysis have elevated demand for robust isotopic standards.

Are Production & Customization Platforms Advancing Availability?

Companies are scaling biosynthesis (microbial fermentation with labeled precursors), chemical synthesis, and enzymatic biotransformations to produce high-purity isotopologues. New platforms support site-specific labeling and multiple-label combinations (e.g., dual ¹³C-¹5N), enabling fine-grained metabolic analysis. Automated purification systems using flash chromatography and HPLC increase throughput and reduce costs.

Turn-around optimization-rapid custom batches for pharma timelines-is supported by digital ordering portals and sample delivery tracking. Multi-isotope kits tailored for drug metabolism studies and microbial flux assessments are boosting usage in CROs and biomanufacturers.

Why Are Researchers Integrating These Tools Across Disciplines?

Quantitative biologists and pharmacologists rely on isotope-labeled standards for absolute concentration measurement, clearance profiling, and drug-drug interaction studies. Systems biologists track natural-product biosynthesis pathways using labeled precursors. Crop and environmental researchers use labeled metabolites to trace uptake and transformation in soil-plant systems. Stable isotope liquid tracers in clinical nutritional studies supply non-invasive tracking of absorption and metabolic fate. Regulatory bodies require labeled internal standards for assay validation and batch release tests in QC labs.

What’s Powering the Growth in the Stable Isotope Labeled Biomolecules Market?

The growth in the stable isotope labeled biomolecules market is driven by several factors related to research precision, production scalability, and interdisciplinary adoption. Advances in fermentation and chemical-labeling methods are reducing costs and expanding availability of complex isotopologues. Increasing global investment in proteomics, metabolomics, and drug pipelines supports demand for high-quality standards. Customized, short-run synthesis and turnkey standard kits meet CRO, biopharma, and academic timelines. Regulatory expectations for precise quantification in drug and food safety assays support widespread adoption. Additionally, partnerships between instrument vendors and isotope suppliers enable integrated workflows-combining labeled standards with sample prep, analytics, and software-accelerating time-to-result and research quality.

SCOPE OF STUDY:

The report analyzes the Stable Isotope Labeled Biomolecules market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (D Labeled Biomolecules, 15N Labeled Biomolecules, 13C Labeled Biomolecules); End-Use (Scientific Research End-Use, Medical End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris (IsoSciences)
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA (Sigma-Aldrich)
  • NIST
  • Nordion (Canada), Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stable Isotope Labeled Biomolecules - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Proteomics and Metabolomics Research Drives Demand for Labeled Biomolecules
    • Rising Adoption of Mass Spectrometry in Life Sciences Propels Use of Stable Isotopes
    • Personalized Medicine and Targeted Drug Development Expand Addressable Research Applications
    • Regulatory Emphasis on Quantitative Bioanalysis Strengthens Business Case for Labeled Standards
    • Increase in Biopharma R&D Budgets Accelerates Demand for High-Purity Stable Isotope Compounds
    • Expansion of Clinical Diagnostics and Biomarker Discovery Spurs Usage in Preclinical Studies
    • Growth in Academic-Industry Collaborations Facilitates Commercial Availability of Custom Molecules
    • Technological Advancements in Labeling Techniques Improve Accuracy and Yield
    • Adoption of Isotope Dilution Techniques in Environmental and Food Testing Broadens Market Scope
    • Outsourcing Trends in Drug Discovery Boost Demand for Third-Party Stable Isotope Services
    • Rising Complexity of Biotherapeutics Drives Requirement for Multi-Isotopic Labeling
    • Globalization of CROs and CDMOs Expands Supply Chain for Labeled Biomolecule Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stable Isotope Labeled Biomolecules Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for D Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for 15N Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for 13C Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Scientific Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Medical End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION